These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 7065569

  • 21. The use of pergolide and lisuride, two experimental dopamine agonists, in patients with advanced Parkinson disease.
    Lieberman AN, Leibowitz M, Gopinathan G, Walker R, Hiesiger E, Nelson J, Goldstein M.
    Am J Med Sci; 1985 Sep; 290(3):102-6. PubMed ID: 4050844
    [Abstract] [Full Text] [Related]

  • 22. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
    Senol MG, Togrol RE.
    Neurology; 2007 Jul 03; 69(1):117; author reply 117-8. PubMed ID: 17606893
    [No Abstract] [Full Text] [Related]

  • 23. Comparative efficacy of two dopamine agonists, pergolide and lergotrile, in Parkinson disease.
    Lieberman AN, Goldstein M, Leibowitz M.
    N Y State J Med; 1988 Aug 03; 88(8):420-2. PubMed ID: 2902541
    [No Abstract] [Full Text] [Related]

  • 24. Double-blind trial of pergolide for Parkinson's disease.
    Diamond SG, Markham CH, Treciokas LJ.
    Neurology; 1985 Mar 03; 35(3):291-5. PubMed ID: 3883232
    [Abstract] [Full Text] [Related]

  • 25. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM, Houeto JL.
    Rev Neurol (Paris); 2002 Jul 03; 158(6-7):744-5. PubMed ID: 12486908
    [Abstract] [Full Text] [Related]

  • 26. Finasteride attenuates pathological gambling in patients with Parkinson disease.
    Bortolato M, Cannas A, Solla P, Bini V, Puligheddu M, Marrosu F.
    J Clin Psychopharmacol; 2012 Jun 03; 32(3):424-5. PubMed ID: 22534502
    [No Abstract] [Full Text] [Related]

  • 27. Cabergoline versus levodopa monotherapy.
    Wheatley K, Clarke CE, Ives N, Gray R.
    Mov Disord; 2004 Jun 03; 19(6):733-4; author reply 734-5. PubMed ID: 15197724
    [No Abstract] [Full Text] [Related]

  • 28. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    Clin Neuropharmacol; 2008 Jun 03; 31(1):19-24. PubMed ID: 18303487
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Re: Cabergoline versus levodopa monotherapy: a decision analysis.
    Marras C.
    Mov Disord; 2004 Jun 03; 19(6):736. PubMed ID: 15197726
    [No Abstract] [Full Text] [Related]

  • 36. Pergolide therapy in Parkinson's disease.
    Jeanty P, Van den Kerchove M, Lowenthal A, De Bruyne H.
    J Neurol; 1984 Jun 03; 231(3):148-52. PubMed ID: 6481422
    [Abstract] [Full Text] [Related]

  • 37. The older Parkinson's disease drugs pergolide and cabergoline have been linked to heart problems. Are there any new Parkinson's drugs which are safer for patients with heart risks?
    Heart Advis; 2009 Aug 03; 12(8):8. PubMed ID: 21188763
    [No Abstract] [Full Text] [Related]

  • 38. Long-term treatment with pergolide: decreased efficacy with time.
    Lieberman AN, Goldstein M, Leibowitz M, Gopinathan G, Neophytides A, Hiesiger E, Nelson J, Walker R.
    Neurology; 1984 Feb 03; 34(2):223-6. PubMed ID: 6538014
    [Abstract] [Full Text] [Related]

  • 39. Treatment of Parkinson's disease.
    Boyson SJ.
    Neurology; 1990 Apr 03; 40(4):725. PubMed ID: 2320258
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.